Bicara Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Bicara Therapeutics Inc.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Boston
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
BCAX
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0002023658

Board of directors

Follow this board

Chief executives

Ryan Cohlhepp · President, COO & Interim CEO Interim
Dates unknown
Claire Mazumdar · Chief Executive Officer
Since September 2024

Director election results

Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 35 other boards. 35 are in the same sector.

Network of Bicara Therapeutics Inc.'s board connections Janux Therapeutics Inc. Janux Therapeutics Inc... Parabilis Medicines Inc. Parabilis Medicines In... Septerna Inc. Septerna Inc. Tyra Biosciences Inc. Tyra Biosciences Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bambusa Therapeutics Inc. Bambusa Therapeutics I... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. LENZ Therapeutics Inc. LENZ Therapeutics Inc. Jake Simson Jake Simson Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Bicara Therapeutics Inc.
Shared director Other board Same sector +19 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$4,800,000
1 purchase by 1 insider
Sold, last 12 months
$9,907,077
57 sales by 4 insiders
Date Insider Transaction Shares Price Value
Sep 8, 2026 Ryan Cohlhepp Director, Officer (President, COO & Interim CEO) Option exercise +17,500 $3.79 $66,325
Sep 8, 2026 Ryan Cohlhepp Director, Officer (President, COO & Interim CEO) Open-market sale −14,058 $22.77 $320,101
Sep 8, 2026 Ryan Cohlhepp Director, Officer (President, COO & Interim CEO) Open-market sale −3,442 $23.43 $80,646
Aug 10, 2026 Ryan Cohlhepp Director, Officer (President and COO) Option exercise +18,750 $3.79 $71,063
Aug 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Option exercise +10,000 $3.79 $37,900
Aug 10, 2026 Hyep Ivan Officer (Chief Financial Officer) Option exercise +12,500 $3.79 $47,375
Aug 10, 2026 Ryan Cohlhepp Director, Officer (President and COO) Open-market sale −18,750 $27.98 $524,625
Aug 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Open-market sale −10,000 $27.98 $279,800
Aug 10, 2026 Hyep Ivan Officer (Chief Financial Officer) Open-market sale −12,500 $27.97 $349,625
Jul 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Option exercise +10,000 $3.79 $37,900
Jul 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Open-market sale −9,972 $28.42 $283,404
Jul 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Open-market sale −28 $29.68 $831
Jul 9, 2026 Ryan Cohlhepp Director, Officer (President and COO) Open-market sale −536 $29.00 $15,544
Jul 8, 2026 Hyep Ivan Officer (Chief Financial Officer) Option exercise +12,500 $3.79 $47,375
Jul 8, 2026 Ryan Cohlhepp Director, Officer (President and COO) Option exercise +18,750 $3.79 $71,063

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States

Questions about Bicara Therapeutics Inc.

Who is the CEO of Bicara Therapeutics Inc.?

Claire Mazumdar has been Bicara Therapeutics Inc.'s Chief Executive Officer since September 2024.

How many directors are on Bicara Therapeutics Inc.'s board?

Bicara Therapeutics Inc.'s board has 14 directors: Carolyn Ng, Christopher Bowden, Christy J. Oliger, Claire Mazumdar, Jake Simson, Jeremy Bender, Kate Haviland, Kiran Mazumdar-Shaw, Michael Powell, Nils Lonberg and 4 others.

Are Bicara Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Bicara Therapeutics Inc. insiders bought $4.8 million of shares in 1 purchase and sold $9.9 million of shares in 57 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Bicara Therapeutics Inc. connected to…? → Spot something wrong? Report a correction
Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here. 

<div data-bod-board="bicara-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.